EDUCATION
East China University of Political Science and Law, Shanghai, P.R. China
Master of International Law, June 2012
Temple University Beasley School of Law, Philadelphia, PA, U.S.A
LL.M. for foreign trained lawyers, May 2011
East China University of Political Science and Law, Shanghai, P.R. China
Bachelor of Law, June 2009
QUALIFICATIONS
State of New York Bar
P.R. China Bar
LANGUAGES
Mandarin (native)
English (fluent)
EXPERIENCE
Silkroad, Anchorite & Sage Law Firm, Shanghai, Partner, 2023-present
Zhong Lun Law Firm, Shanghai, Partner, 2022-2023
Zhong Lun Law Firm, Shanghai, Associate, 2012-2015, 2016-2021
Ample-Harvest Capital, Shanghai, Senior Legal Counsel, 2015- 2016
PRACTICES
Investment Fund, Private Equity, M&A
PROFESSIONAL HONORS
2023The Legal 500＞ASIA PACIFIC＞China Private Equity＞Rising Stars
2022 The Legal 500＞ASIA PACIFIC＞China Private Equity＞Rising Stars
DEAL LIST
Represented IDG Capital in IDG Sport Industry Investment Fund formation, IDG Tourism Fund formation and IDG and Sichuan Shuangma (000935) Jointly Industrial Buy-out Fund formation.
Represented Boyu Capital in Boyu Vanke Warehouse Logistics Investment Fund formation.
Represented Redpoint in RMB PE Fund II formation.
Represented China Eastern Airline in Aviation Industry Fund formation.
Represented Inspiration Fund in RMB VC Fund I formation, RMB VC Fund II formation and RMB Green PE fund formation.
Represented Guohe Capital in Modern Service Industry Service Investment Fund II formation and Jointly Healthcare Fund with a listed company formation.
Represented China Insurance Investment Co. in China Insurance Investment Fund II formation.
Represented Jianxin Capital in Jianxin Healthcare Fund formation.
Represented Xiamen C&D Capital in a Secondary Fund formation.
Represented Proxima Capital in Healthcare Fund I, Fund II and Fund III formation.
Represented Future X Capital in RMB VC Fund I formation.
Represented Allin Capital in RMB Semiconductor VC Fund II formation and RMB Semiconductor Angel Investment Fund formation.
Represented Yuemeng Capital (subsidiary of Shui On) in RMB VC Fund formation.
Represented Pingan Trust in Onshore fund formation and its investment in Autohome.
Represented SSIC Capital FOF in its investments in Walden RMB VC Fund IV,Walden RMB VC Fund III, DT Capital RMB Fund III, GP Healthcare Fund II. BRV Fund II and ZJ Innopark Fund.
Represented China Insurance Investment Fund II in its investment in Guosheng Fund II.
Represented CPIC in its investment in China's State Owned Capital Venture Capital Fund.
Represented Lingang Group in its investment in GP Healthcare Fund II.
Represented Shanghai Industry Transformation Upgrading Investment Fund in its investment in GP Healthcare Fund III.
Represented Shanghai Technology Venture Capital in its investment in several RMB Funds.
Represented Pingan Trust in its investment in Sequoia Capital RMB Fund III.
Represented Noah in its investments in Meituan Dianping Fund, BRV Fund II.
Represented China Insurance Investment Co. in a estate fund formation and investment projects in cooperation with Poly Developments and Holdings.
Represented TISHMAN SPEYER, Noah, Gopher Asset, Chenxi Real Estate Fund, Pingan Trust, Zhongrong Trust, Cura Fund, Aijian Trust in several real estate fund, trust formation and investment projects.
Represented Shanghai International Group, as anchor investor, in its investment in Sailing Fund II
Represented Proxima Capital in Hillhouse’s investment in Proxima USD Fund.
Represented Ping An Life Insurance in its investment in Global Infrastructure Partners III Fund.
Represented CPIC in its investment in Providence Equity VIII Fund.
Represented Ctrip in its investment in Ocean Link Fund II and INCE Fund.
Represented Gopher Asset in its investment in several USD funds: Lunar Capital Fund IV, Lyfe Capital Fund, Walden VC Fund II, C-Bridge Healthcare Fund and Zhen Partners Fund III, L.P.
Represented Cathay Fund in its investment in Cedar (Series B and Series C), Jiuye Supply Chain (Series B+), Wuxi Taclink Technology Co. (Series C), BrosMed Medical (Series C), Deerma (Series C), UV Clinic (Series Pre-IPO), Mistine Cosmetics,and a leading global cosmetics OEM/ODM company (strategic investment).
Represented Vertex Ventures in its Series A investment in an ADC pharmaceutical company.
Represented BioTrack Capital and 6 Dimensions Capital in its Series A investment in a pharmaceutical company.
Represented Ming BioVentures in its Series B investment in Carelyfe Co.
Represented Gaocheng Capital in its Series D investment in Huisuanzhang.
Represented Proxima Capital in its investments in several medical start-ups
Represented Sogo in its investments in several TMT start-ups
Represented Pingan Caizhi in its Series Pre-IPO investment in a semiconductor company
Represented SSIC Capital in its investment in Golden Cloud, XYNM
Represented Puxin Capital in its investments in Xunce Technology, XYLink Technology, Tsingj Technology
Participate in Ample-Harvest Capital investment in several start-up companies as its in-house counsel.
Represented Hongxin Technical in its Series Pre-IPO financing (RMB 3.675 billion) which China Development Investment Fund as leading investor.
Represented Forerunner Medical in its Series B financing (RMB 150 million), Series B+ financing (RMB 100 million) which CICC Capital as leading investor and its cross over financing (on-going).
Represented Lianlian Pay in its domestic and overseas restructuring.
Represented Good Smile in its domestic and overseas structure designing and restructuring.
Represented a medical device company to advice on restate of investors preferential rights in its public offering in HKEX.
Represented Eight Roads to advice on legal related matters with respect to the public offering of Eyebright Medical, including restatement of investors preferential rights, shareholder covenant and other legal related matters, and on legal related matters with respect to reduction in shareholding afterwards.
Represented Cathay Fund in exiting its investment in M Cake.
Participate in Ample-Harvest Capital exiting its investment from Yitiao as its in-house counsel.
Represented IDG Capital to advice on legal related matters with respect to the public offering of Project JML.
Represented Future X Capital, Envision Capital, Gopher Asset to advice on legal related matters with respect to the public offering of their protfolios.
Represented Guohe Capital, Goodhealth Capital, Shanghai SIIC Fund Management, Gaocheng Capital to advice on legal related matters with respect to their protfolios’ domestic and overseas restructuring.
Represented multiple clients to advice on compliance and dispute resolution matters, including matters related to partners' overdue capital commitment, default of portfolios, compliance issues with respect to portfolio investment, etc.
Represented Lianlian Pay in its acquisitions of Dai 163, Factor 163.
Represented Forerunner Medical in its acquisitions of Anzhen Medical.
Represented Sunshine Capital in its sale of a commercial property to Starcast Capital.
Represented Banyan Tree to complete the first stage of the acquisition and restructuring of certain hotel assets in China with Vanke (MOU signing and announcement).
Represented Brightcity in its sale of a warehouse property to Logos.
Equity Incentive for multiple clients (including fund managers, start-ups, etc).
Represented Sogo and other corporate clients and high-net-worth individuals to provide services for the restructuring of their investment portfolios.
Submitted successfully
We will get in touch with you as soon as possible